According to the National Healthcare Security Administration, from August 12 to August 18, 2025, the National Healthcare Security Administration publicly announced the list of drugs that have passed the preliminary form review for the adjustment of the 2025 National Basic Medical Insurance, Maternity Insurance, Work Injury Insurance Drug Catalog, and Commercial Insurance Innovative Drug Catalog. During the public announcement period, a total of 75 feedback comments were received.

According to the collected opinions, the National Healthcare Security Administration has reviewed and revised the relevant drug review results in accordance with the procedures. A total of 6 drug form review results have changed, all of which are drugs that have applied for the basic medical insurance catalog. The specific situation is:

1. Change the status of injectable risperidone microspheres to not pass the formal review;

2. Change the form review of triptorelin hydrochloride for injection to not pass;

3. Levodopa injection has passed the formal examination and meets the conditions for declaration outside the catalog;

4. The injection of calcium gluconate and sodium chloride has passed the formal examination and meets the conditions for declaration outside the catalog;

5. Ceftriaxone Sodium and Sulbactam Sodium for Injection have passed the formal review and meet the conditions for declaration outside the catalog;

6. Ursodeoxycholic acid oral suspension passed the formal examination, but the examination result was changed to meet the out of catalog declaration conditions of 1/4/5.

In the final stage of the 2025 directory adjustment application, the National Medical Insurance Administration received a total of 718 applications for the basic medical insurance directory, involving 633 generic names of drugs. 535 of them passed the formal review, including 311 outside the directory and 224 inside the directory. 141 applications were submitted for the commercial insurance innovative drug catalog, involving 141 generic names of drugs. 121 of them passed the formal review, including 79 applications for both the basic medical insurance catalog and the commercial insurance innovative drug catalog.

In addition, in some non exclusive varieties, the same generic name is declared by different companies under different conditions, and formal examination is conducted based on the application conditions of the companies. Only drug companies that pass the formal examination can participate in the next step of work. Through formal examination, it only represents that the drug meets the corresponding application conditions and has obtained the qualification to participate in expert review. Only drugs that have passed all stages of evaluation, negotiation, etc. can be finally included in the catalog.

Next, the National Healthcare Security Administration will organize expert reviews and other work in accordance with the requirements of the "Interim Measures for the Administration of Basic Medical Insurance Medications" and the "2025 Work Plan for Adjusting the National Basic Medical Insurance, Maternity Insurance, Work Injury Insurance Drug Catalog, and Commercial Health Insurance Innovative Drug Catalog". Please pay attention to the "2025 National Medical Insurance Drug Catalog Adjustment Application Module" on the National Medical Insurance Service Platform, and obtain timely information on the review, evaluation, negotiation, agreement signing, and other forms of catalog adjustment.